BFRI
HEALTHCAREBiofrontera Inc
$1.14-0.01 (-0.87%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BFRI Today?
No stock-specific AI insight has been generated for BFRI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.54$1.19
$1.14
Fundamentals
Market Cap$14M
P/E Ratio—
EPS$-1.04
Dividend Yield—
Dividend / Share—
ROE-1.4%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume216K
Avg Volume (10D)—
Shares Outstanding12.0M
BFRI News
20 articles- Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026Yahoo Finance·May 8, 2026
- Rapport Therapeutics, Inc. (RAPP) Reports Q1 LossYahoo Finance·May 7, 2026
- Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...Yahoo Finance·Mar 21, 2026
- Biofrontera Inc. Q4 2025 Earnings Call SummaryMoby·Mar 19, 2026
- Biofrontera (BFRI) Q4 2025 Earnings TranscriptMotley Fool·Mar 19, 2026
- Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateYahoo Finance·Mar 19, 2026
- Are Medical Stocks Lagging Align Technology (ALGN) This Year?Yahoo Finance·Mar 11, 2026
- Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026Yahoo Finance·Mar 9, 2026
- Biofrontera Inc. (BFRI) Upgraded to Buy: Here's WhyYahoo Finance·Mar 9, 2026
- Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne VulgarisYahoo Finance·Mar 9, 2026
- U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be UnpatentableYahoo Finance·Feb 26, 2026
- Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and ExtremitiesYahoo Finance·Feb 17, 2026
- Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell CarcinomaYahoo Finance·Feb 11, 2026
- Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary EndpointYahoo Finance·Feb 9, 2026
- Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock NowYahoo Finance·Feb 5, 2026
- Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Feb 5, 2026
- Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year GrowthYahoo Finance·Jan 13, 2026
- Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory MilestonesYahoo Finance·Jan 8, 2026
- Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property PortfolioYahoo Finance·Dec 18, 2025
- Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and ExtremitiesYahoo Finance·Dec 4, 2025
All 20 articles loaded
Price Data
Open$1.13
Previous Close$1.15
Day High$1.19
Day Low$1.13
52 Week High$1.19
52 Week Low$0.54
52-Week Range
$0.54$1.19
$1.14
Fundamentals
Market Cap$14M
P/E Ratio—
EPS$-1.04
Dividend Yield—
Dividend / Share—
ROE-1.4%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume216K
Avg Volume (10D)—
Shares Outstanding12.0M
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—